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Abstract
Background: Current use of prescribed or over the counter non-steroidal anti-inflammatory drugs (NSAIDs) for
pain and osteoarthritis (OA) have untoward gastrointestinal and cardiovascular related side effects, as a result the
need for a safe and effective alternative has become unequivocally crucial.
Method: A randomized, double blind, placebo and active controlled pilot study of a novel dual pathway, COX1/2 and
LOX, inhibitor anti-inflammatory agent of botanical origin, UP446 was conducted. Sixty subjects (age 40-75) with
symptomatic OA of the hip or knee were assigned to 4 treatment groups (n = 15); Group A0 (Placebo, CMC capsule),
Group A1 (UP446 250 mg/day), Group A2 (UP446 500 mg/day) and Group A3 (Celecoxib, 200 mg/day). MOS-SF-36 and
Western Ontario and McMaster University Osteoarthritis Index (WOMAC) data were collected at baseline and after 30, 60
and 90 days of treatment as a measure of efficacy. Erythrocyte sedimentation rate, C-reactive protein, plasma thrombin
time (PTT), fructosamine, Hematology, clinical chemistry and fecal occult blood were monitored for safety.
Results: Statistically significant decrease in WOMAC pain score were observed for Group A1 at day 90, Group A2 at
30 and 90 days and Group A3 at 60 and 90 days. Statistically significant decrease in WOMAC stiffness score were
observed for Group A1 and Group A2 at 30, 60 and 90 days; but not for Group A0 and Group A3. The mean
change in WOMAC functional impairment scores were statistically significant for Group A1 and Group A2
respectively at 30 days (p = 0.006 and p = 0.006), at 60 days (p = 0.016 and p = 0.002) and at 90 days (p = 0.018
and p = 0.002), these changes were not significant for Group A0 and Group A3. Based on MOS -SF-36
questionnaires, statistically significant improvements in physical function, endurance and mental health scores were
observed for all active treatment groups compared to placebo. No significant changes suggestive of toxicity in
routine hematologies, serum chemistries, liver enzymes or PTT were noted in any of the treatment groups.
Conclusion: Based on current findings UP446 is safe and efficacious alternative to established anti-inflammatory
medications for alleviating OA symptoms as measured by the WOMAC Index.
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Introduction
Osteoarthritis (OA) is the most common form of joint
disorder and the most frequent cause of musculo-skele-
tal disability worldwide [1,2]. As the population ages,
the number of affected people with OA is expected to
reach 60 million by the year 2020 [1]. In the United
States, alone, there are 40 million people with this dis-
ease who cost the economy an estimated $60 billion
yearly [1].
On a biochemical level the primary feature of OA is the
accelerated metabolism of arachidonic acid (AA) gener-
ated from cell membranes by the action of phospholi-
pase. AA is metabolized by two parallel pathways,
cyclooxygenase and 5-lipoxygenase to yield a variety of
physiologically active compounds, notably prostaglandins
* Correspondence: lbrownell@unigen.net
3Unigen Inc., 2260 Willamette Drive NE, 98516 Lacey, Washington, USA
Full list of author information is available at the end of the article
Sampalis and Brownell Nutrition Journal 2012, 11:21
http://www.nutritionj.com/content/11/1/21
© 2012 Sampalis and Brownell; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.and leukotrienes, respectively. Many of these molecules
are involved in the inflammatory response [3].
Present day OA medications act by blocking one or
both of the cyclooxygenase (COX-1, COX-2) pathways
resulting in reduction of inflammatory mediators such as
prostaglandins and prostacyclins. Unfortunately, this
therapeutic action is also responsible for most of the toxi-
city of these agents. It is thought that blocking the COX
pathway(s) shunts more AA metabolism down the 5-
LOX path with a resultant increase in levels of highly
chemotactic and inflammatory leukotrienes [4]. LTB4
has been shown to stimulate osteoclastic bone resorption
[5] and has been detected at high levels in the walls of
NSAID induced gastric ulcers [6]. LTB4 is also associated
with increased production of the pro-inflammatory cyto-
kines TNFa and IL-1b [7,8]
The class of anti-inflammatory agents, called dual path-
way inhibitors more recently developed, blocks all three
of the primary AA metabolic pathways and seem to have
a more benign toxicity profile than traditional medica-
tions. [9]. Dual inhibitors seem not to cause GI damage;
rather, they show protective effects on GI mucosa. Potent
anti-inflammatory action associated with fewer side
effects is the desired outcome but needs confirmation
from clinical studies.
UP446 is a proprietary, standardized blend of extracts
from two botanical sources that have been used medicin-
ally in China and India for more than 1000 years. The
extracts contain free B-ring flavonoids and flavans stan-
dardized to baicalin and catechin. In preclinical studies it
has been shown to inhibit COX-1, COX-2 and 5-LOX
and to block several animal models of inflammation
[10,11]. The findings of this study suggest that a standar-
dized composition of UP446 has an effect on pain, stiff-
ness and physical function as evaluated by the WOMAC
questionnaire.
Purpose
This study was conducted to compare the effect and
safety of two dosages of UP446 as compared with Cele-
coxib and placebo in subjects with osteoarthritis (OA)
of the knee or hip.
Materials and methods
Study design
This was a randomized, double blind, placebo and active
comparator controlled study. The study was conducted
according to ICH guidelines and under independent
institutional review board oversight. An independent
review board approved the protocol and all subjects were
required to provide written informed consent prior to
enrollment and administration of medication or any
study procedures. Study subjects were recruited from the
practices of primary care physicians in Montreal, Quebec.
Subjects that met the inclusion/exclusion criteria were
randomly assigned to 1 of the 4 study groups (Table 1).
Study Population
Subjects were ambulatory men or women, 40-75 years
old and had evidence of measurable symptoms of
osteoarthritis of the knee and/or hip requiring the use of
acetaminophen, including COX -2 inhibitors, anti-
inflammatory agents or opioid analgesics as treatment
medications. There were no significant differences
between the four groups with respect to demographic
characteristics (Table 2).
Major inclusion criteria
1. Age between 40 and 75 years; both genders
admissible.
2. Evidence of measurable symptoms of osteoarthritis
of the knee and/or hip requiring the use of acetamino-
phen, anti-inflammatory agents or opioid analgesics.
3. Patients were asked to stop use of all other “pain-
killers” (except acetaminophen) the week prior to initia-
tion of the trial for washout purposes.
4. Intention to fully participate in study including
attending physician appointments during trial.
Major exclusion criteria
1. Patients with a history of cardiovascular or renal
disease, peptic ulcer disease with or without gastroin-
testinal hemorrhage or perforation or uncontrolled dia-
betes mellitus were excluded.
2. The concomitant use of NSAIDs, including COX-2
inhibitors, H2 blockers or proton pump inhibitors was
not allowed
3. Patients who had begun a new physical therapy
regime within three months of screening were also
excluded as were those with a history of allergy to flavo-
noids, NSAIDs, aspirin or acetaminophen
Acetaminophen was provided as rescue medication.
Subjects were permitted to take up to 1000 mg t.i.d.
Measurements
Safety was measured by physical examinations, vital
signs, monthly hematology and chemistry laboratory
studies, thrombin time, fecal occult blood and treatment
Table 1 Subject randomization
Group Name Sample size Compound Dosage
A0 Placebo n = 15 Placebo N/A (CMC capsule b.i.d)
A1 Dose 1 n = 15 UP446 250 mg/day (125 mg b.i.d.)
A2 Dose 2 n = 15 UP446 500 mg/day (250 mg b.i.d.)
A3 Dose 3 n = 15 Celecoxib 200 mg/day (100 mg b.i.d.)
Acetaminophen was provided as rescue medication. Subjects were permitted
to take up to 1000 mg t.i.d.
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sured with self-administered questionnaires, specifically
the MOS-SF36 and Western Ontario and McMaster
University Osteoarthritis Index (WOMAC) that were
completed at baseline and after 30, 60, and 90 days of
treatment. Laboratory measures of efficacy included
ESR, CRP, and fructosamine at baseline and after
90 days of treatment.
Statistical methods
The primary outcome measure for efficacy was the subjec-
tive assessment of pain as measured by the Western
Ontario and McMaster University Osteoarthritis Index
(WOMAC). Additional functional outcome measurements
were evaluated with the Short Form SF-36. The Western
Ontario and McMaster University Osteoarthritis Index
(WOMAC) has been widely accepted as a valid tool for
the classical measurement of osteoarthritis symptom
quantification [12]. The Health Assessment Questionnaire
Short Form SF-36 has been designed for use in clinical
practice and research, health policy evaluations and gen-
eral population surveys. It includes one multi-item scale
that assesses eight health concepts: 1) limitations in physi-
cal activities because of health problems; 2) limitations in
social activities because of physical or emotional problems;
3) limitations in usual role activities because of physical
health problems; 4) bodily pain; 5) general mental health
(psychological distress and well-being); 6) limitations in
usual role activities because of emotional problems; 7)
vitality (energy and fatigue); and 8) general health
perceptions.
Within group changes in the efficacy measures were
assessed using the paired Student’s t-test. Between groups
differences with respect to the change in the efficacy mea-
sure were assessed with analysis of variance (ANOVA).
Multiple-linear regression analysis was used to adjust for
the effect of potential confounders. Safety was evaluated
by the incidence of adverse events and change in labora-
tory test results. Relative rate estimates were used to com-
pare the groups with respect to the incidence of adverse
events. Paired Student’s t-test was used to assess the
change in the laboratory test parameters.
Raw/non standardized values for the WOMAC scores
w e r eb a s e do naf i v ep o i n tL i k e r ts c a l ew i t h5r e s p o n s e
options ranging from ‘none’ to ‘extreme’. A response of
‘none’ is scored as 0, ‘mild’ as 1, ‘moderate’ as 2, ‘severe’ as
3, and ‘extreme’ as 4. Scores for each section were
summed to produce pain, stiffness, and physical function
Scores.
Standardization to a scale between 0 and 100 was used
for uniformity and to enhance the appreciation of the
magnitudes of changes. The mean percent change and
p value from baseline are calculated from the normal-
ized scores.
Statistical Analysis was performed by JSS Medical
Research Inc.; Montreal Quebec.
Results
Sixty subjects were enrolled in the study, 22 (36.7%)
men and 38 (63.3%) women, mean (SD) age 57.6 (13.2)
years. There were no statistically significant differences
between the four groups with respect to demographic
characteristics and baseline disease activity.
Of the 60 subjects who enrolled, 52 (87%) completed the
study (Table 3). One patient from the UP446 250 mg/day
g r o u pw a sr e m o v e df r o mt h es t u d ya t4 0d a y sd u et o
urgent requirement for hip surgery. Two subjects in the
UP446 500 mg/day group withdrew after 60 days for per-
sonal reasons. From the celecoxib 200-mg/day group,
2 patients withdrew at 30 days because of positive fecal
occult test and 1 patient withdrew at 90 days for personal
reasons. From the placebo group, 2 patients withdrew
after 60 days, 1 for personal reasons and 1 because of
noticeable reduced flexibility.
WOMAC
The mean WOMAC scores and mean percent change
from baseline at the 30, 60, and 90 day evaluations are
summarized in Figures 1, 2 and 3.
WOMAC pain scores
Significant decreases in the mean WOMAC pain score
were observed for the UP446 250 mg/day group at 90 days
(p = 0.045), and for the UP446 500 mg/day group at 30
days (p = 0.001), and 90 days (p = 0.001) but not at 60
days ( p = 0.102). For the Celecoxib group significance was
observed at 60 days (p = 0.004) and at 90 days (p = 0.021)
but not at 30 days (p = 0.375). The overall within group
effect for all visits combined was significant for the UP446
group 500 mgs/day (p = 0.002) and the Celecoxib (p =
0.003) groups only. There were some small changes from
baseline for the placebo group but statistical significant
was not reached. (Table 4)
Table 2 Subject demographics
UP446250 mg/day UP446500 mg/day Celecoxib200 mg/day Placebo
Total (N) 15 15 15 15
Mean (SD) Age 62.8 (10.8) 54.6 (14.8) 57.6 (12.6) 55.3 (14.3)
Male N (%) 5 (33) 6 (40) 5 (33) 6 (40)
Female N (%) 10 (67) 9 (60) 10 (67) 9 (60)
Sampalis and Brownell Nutrition Journal 2012, 11:21
http://www.nutritionj.com/content/11/1/21
Page 3 of 9WOMAC stiffness scores
Significant decreases in the mean WOMAC stiffness
score were observed for the UP446 250 mg/day group at
30 days (p = 0.004), 60 days (p = 0.002) and 90 days (p
= 0.003), and for the UP446 500 mg/day group at 30
days (p = 0.002), 60 days (p = 0.043) and 90 days (p =
0.001). For the celecoxib and placebo groups no signifi-
cant within group changes were observed (Table 5).
WOMAC functional impairment scores
The mean change in WOMAC functional impairment
scores were significant for the UP446 250 mg/day and
the UP446 500 mg/day groups respectively at 30 days (p
= 0.006 and p = 0.006), at 60 days (p = 0.016 and p =
0.002) and at 90 days (p = 0.018 and p = 0.002). For
these two groups the overall within group effect across
all visits was significant (p = 0.018) and (p = 0.001)
respectively. The changes in functional impairment over
time were not significant for the Celecoxib and placebo
groups. (Table 6)
MOS SF-36 questionnaires
The intra-group 30, 60 and 90 SF-36 scores for pain and
function in all treatment groups are shown in Tables 7
and 8. Significant improvement in physical function was
observed at all follow up visits (p = 0.001) for all groups
except the placebo.
T h ec h a n g ei np h y s i c a lr o l ew a ss i g n i f i c a n tf o rU P 4 4 6
250 mgs/day group at 30 days (p = 0.031), 60 days (p =
0.004) and at 90 days (p = 0.041). For the UP446 500 mg/
day significant improvement in physical role was observed
at 30 days only (p = 0.002). The Celecoxib 200 mgs/day
group experienced significant improvement in physical role
at 30 days (p = 0.008), at 60 days (p = 0.001) and at 90
days (p =0.004). The placebo group did not have significant
changes in physical role. All three of the active treatment
groups, but not the placebo group, had significant
improvement in the energy/fatigue and mental health
scores (p < 0.001). There were no significant changes in
the general health scores over time for all study groups.
Between group analyses
The following sections describe the results of the one
-way ANOVA and post-hoc comparisons for between
group differences in respect to change in the WOMAC
and MOS-SF 36 scale scores.
WOMAC
In the WOMAC score significant differences were
observed at 30, 60 and 90 days in pain while walking on a
flat surface. Similar, but less pronounced differences were
seen between groups. With respect to pain, UP446 and
Celecoxib scored better than placebo at 60 and 90 days.
The WOMAC inter-group comparisons for pain, stiffness
Table 3 Final subject disposition by group and visit
Group
UP446250 mgs/day UP446500 mgs/day Celecoxib 200 mgs/day Placebo
Visit Baseline 15 15 15 15
30 Days 15 15 13 15
60 Days 14 13 13 13
90 Days 14 13 12 13
* P=0.05 and **P=0.001 Vs baseline. 
Figure 1 Change in WOMAC Pain Scores/100 by Visit and
Study Group. Statistical significant changes from baseline were
observed during the 90 day study with UP446 500 mgs/day group
reaching significance earlier at 30 days.
* P=0.05 and **P=0.001 Vs baseline. 
Figure 2 Change in WOMAC Stiffness Scores/100 by Visit and
Study Group. UP446 250 mgs/day and UP446 500 mgs/day groups
had consistently statistical significant changes from baseline during
the study.
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reached statistical significance in the WOMAC pain scale
over UP446 250 mgs at 90 days and over placebo at 30,
60 and 90 days. For stiffness UP446 500 mgs was signifi-
cant at 30 and 90 days over placebo. In the WOMAC
function scale UP446 500 mgs showed significance over
placebo and Celecoxib at 30, 60 and 90 days.
UP446 at 250 mgs was significant over placebo on
stiffness at 60 and 90 days and over Celecoxib at 30
days on the function scales. Celecoxib was statistically
significant at 60 days over placebo on the pain scale, at
30 days on the stiffness scale and at 30, 60 and 90 days
on the Function scale of the WOMAC. (Table 9)
MOS-SF 36
For the MOS-SF 36, the mean change in the SF-36
function score was significantly different for the four
treatment groups at 30, 60 and 90 days ( p = < 0.001).
At 30 and 60 days significant differences were observed
in physical function score between the placebo group
and the active treatment groups (p = < 0.001). Tukey’s
LSD test showed that at 90 days significant differences
existed between UP446 250 mg/day and celecoxib (p =
0.035), UP446 500 mg/day and celecoxib (p = 0.020)
and between placebo and the three active treatment
groups (p = < 0.001). All three of the active treatment
groups, but not the placebo group, had significant
improvement in the energy/fatigue and mental health
scores (p < 0.001).
S i m i l a r l yt h ec h a n g e si np h y s i c a lr o l es c o r e sw e r ed i f -
ferent between the four groups at 30 days (p = 0.012)
60 days (p = 0.012) and at 90 days (p = 0.009). At 30
days significant differences were observed between the
Placebo group and UP446 250 mgs/day (p = 0.015) and
celecoxib (p = 0.002). At 60 days the statistically signifi-
cant comparisons were between UP446 500 mgs/day
and celecoxib (p = 0.019), between Placebo and UP446
250 mgs/day (p = 0.024) and between placebo and cele-
coxib (p = 0.004). Similarly differences were observed at
90 days between UP446 500 mgs/day and celecoxib (p =
0.030) and between placebo and the two UP446 groups
(p = 0.020).
The changes in energy/fatigue score were different
between the four groups at 30 days (p = 0.001), 60 days
(p = 0.011) and at 90 days (p = 0.001). At the 30, 60
and 90 days the significant differences were between the
* P=0.05 and **P=0.001 Vs baseline.
Figure 3 Change in WOMAC Functional Scores/100 by Visit
and Study Group. Statistical significant change in Functional
Scores was only observed in the UP446 treatment groups, UP446
250 mgs/day and UP446 500 mgs/day.









Visit Baseline Mean 3.17 3.41 3.20 2.97
Std Deviation 0.80 0.93 0.89 0.60
30 Days Mean 2.65 2.44 3.00 2.67
Std Deviation 0.77 0.92 0.92 0.62
60 Days Mean 2.63 2.63 2.20 3.29
Std Deviation 0.66 0.79 0.66 0.67
90 Days Mean 2.67 2.11 2.27 3.00
Std Deviation 0.65 0.86 0.66 0.58












Visit Baseline Mean 3.53 3.47 2.90 2.87
Std
Deviation
1.08 0.95 0.87 0.85
30 Days Mean 2.67 2.77 2.58 3.37
Std
Deviation
0.65 0.84 0.73 0.83
60 Days Mean 2.50 2.58 2.50 2.85
Std
Deviation
0.76 0.79 1.19 0.99
90 Days Mean 2.57 2.15 2.17 2.96
Std
Deviation
0.83 0.85 1.01 0.72
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(p = 0.001). There were no significant between group
differences with respect to pain scores. The change in
mental health scores was significantly different between
the four groups at 30, 60 and 90 days (p = 0.001). These
differences could be due to significantly lower mean
changes in the placebo group when compared to the
three active treatment groups (p = 0.001).
There were no significant between group differences
with respect to the changes in social function, emotional
role or general health.
Laboratory measures of efficacy
C-reactive protein (CRP) data were collected as a marker
of inflammation; [13,14]. There was a decrease for the
UP446 250 mgs group and the Celecoxib group and a
slight increase for the placebo and the UP446 500 mgs
group. These changes are not statistically significant for
the groups except for the 250 mgs UP446 group change
from baseline at 90 days. Most of the changes have little
clinical significance due to slight changes that can be
attributed to individual and or analytical variability. The
second clinical inflammation marker used was the erythro-
cyte sedimentation rate (ESR). The changes were not sta-
tistically or clinically significant for any group all the
groups mean values considering the age and gender mix,
fall within normal clinical reference range. During the
pilot study data was not collected for other markers of
inflammation such as cytokines (IL-6, TNF alpha, etc)
therefore a conclusion on the specific role of UP446 anti-
inflammatory properties cannot be made based on this
study [15,16].
The fructosamine levels can give an indication of the
average glucose levels over the past 2 to 3 weeks, during
the study there were not significant changes between
groups but the changes from baseline were significant
for all groups. These changes correlated well with the
moderate decrease in glucose and body weight changes
observed for the groups.
Safety evaluations
No significant changes were noted in routine hematolo-
gies, serum chemistries, liver enzymes or Partial Thrombin
time (PTT) in any of the treatment groups.
The PTT was used as a safety marker due to reported
inadequate platelet function of drug induced etiology
such as aspirin, NSAIDs or liver injury. The PTT values
were very consistent for all the groups with no signifi-
cant or clinical changes from baseline.
The fecal occult blood Test (FOBT) was also used as a
safety evaluation of the treatment groups. Nonsteroidal
anti-inflammatory drugs (NSAIDs) increase the risk of
upper gastrointestinal bleeding. Four NSAIDs commonly
used (indomethacin, naproxen, diclofenac, and piroxicam)
Table 7 SF-36 pain scale scores by group and visit








Baseline Mean 8.53 7.53 8.20 7.40 0.272
Std Deviation 1.85 2.17 1.86 1.24
30 Days Mean 7.53 7.67 8.46 7.33 0.325
Std Deviation 1.41 1.95 .97 2.06
60 Days Mean 7.29 7.38 8.08 7.31 0.643
Std Deviation 1.49 2.06 1.93 1.80
90 Days Mean 7.50 6.54 7.50 7.54 0.547
Std Deviation 2.03 1.98 2.50 1.76









Visit Baseline Mean 3.34 3.52 2.98 3.11
Std Deviation 0.91 0.71 0.41 0.33
30 Days Mean 2.68 2.90 2.94 3.08
Std Deviation 0.58 0.69 0.37 0.59
60 Days Mean 2.66 2.66 2.65 2.99
Std Deviation 0.31 0.29 0.36 0.29
90 Days Mean 2.70 2.52 2.78 3.04
Std Deviation 0.68 0.53 0.44 0.51
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from 4.9 to 19.1 for subjects who used the drug at least
once during the week before symptoms began. Aspirin
was also associated with a substantially increased risk of
bleeding (odds ratio, 7.2); acetaminophen was not [17].
There were 20 subjects with a positive FOBT at the dura-
tion of the study. Positive FOBT were distributed among
all groups to include the placebo, no frank bleeding was
reported. (Table 10)
In both UP446 groups mean systolic blood pressure
decreased from 146 at baseline to 125 at the 30 day visit
and remained stable thereafter. This change was not
seen in the celecoxib or placebo groups. Diastolic blood
pressure and resting pulse did not change during the
course of the study.
There were no differences in type or frequency of
symptomatic adverse events between the UP446 and
placebo groups. Interestingly, all three active treatment
groups experienced weight loss, with BMI changes of
between 1.6-2.4 kg/m
2.
It is unclear if this is a metabolic effect of the pro-
ducts or reflects increased activity associated with symp-
tomatic improvement. Other observations noted during
adverse effects monitoring for safety are listed below.
These events were not classified as treatment related by
the Investigator (Table 11).
Discussion
This study describes the results of a first pilot clinical
trial of UP446 in OA subjects. UP446 is a novel dual
pathway inhibitor of botanical origin. The effects of two
different doses of this plant extract were evaluated on
osteoarthritis and compared to placebo and Celecoxib.
This study demonstrated that UP446 at both dose levels
and Celecoxib were associated with significant reduction
in pain, stiffness and functional incapacity as compared
to placebo. Although the treatment groups were small,
the results strongly suggest that UP446 at 500 mgs per
d a yw a ss i g n i f i c a n t l ym o r ee f f e c t i v et h a nC e l e c o x i ba t
200 mgs for pain reduction and improvement in
Table 8 SF - 36 Physical function scores by group and visit








Visit Baseline Mean 19.53 19.93 21.07 19.40 0.170
Std
Deviation
1.88 2.15 2.19 2.61
30 Days Mean 26.73 27.00 27.00 20.67 0.001
Std
Deviation
1.49 1.07 2.08 1.72
60 Days Mean 27.21 26.77 27.31 21.15 0.001
Std
Deviation
1.31 1.92 1.44 2.08
90 Days Mean 26.36 27.23 25.92 20.23 0.001
Std
Deviation
1.01 1.54 1.00 1.79




















UP446 500 mgs vs.
UP446 250 mgs
NS* NS 0.038 NS NS NS NS NS NS
UP446 250 mgs vs.
CELECOXIB 200 mgs
NS NS NS NS NS NS 0.010 NS NS
UP446 500 mgs vs.
CELECOXIB 200 mgs
0.020 NS NS NS NS NS 0.015 0.043 0.039
UP446 250 mgs vs.
PLACEBO
NS NS NS 0.000 0.027 0.015 0.010 0.043 0.039
UP446 500 mgs vs.
PLACEBO
0.044 0.032 0.001 0.001 NS 0.005 0.015 0.016 0.003
CELECOXIB 200 mgs
vs. PLACEBO
NS 0.009 NS 0.023 NS NS 0.015 0.016 0.003
*NS: Not statistically significant
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offer an alternative way of dealing with the discomfort
associated with osteoarthritis, there are many NSAIDs
available but their major side effects are well known
[18]. There are some limitations and interesting findings
in this pilot study. For example, the statistical findings
in changes from baseline (p value < 0.05) were not con-
s i s t e n ta tt h e3 0 ,6 0a n d9 0d a y st i m ep o i n t sf o ra n yo f
the study groups. For the pain the scores, the UP446 at
both dose levels has significance at 30 and 90 days but not
at 60 days in contrast the celecoxib group at 60 and 90
days but not at 30 days. Review of the study shows that
the average change in WOMAC pain score (Figure 1) for
UP446 at 250 mgs was remarkably close for the 30, 60 and
90 day measurement; mean -13 at 30 days, -14.64 at 60
days and -13.57 at 90 days. In fact the value at 60 days is if
anything suggestive of a better result than the 30 day and
90 day values (Figure 1). We conclude that any “statistical”
differences between the values are therefore due to differ-
ences in variance (standard deviation), which results in the
60 day value having marginally less statistical significance
than the 30 day and 90 day values. Thus while only the 90
day value achieved p < =0.05, in fact the 30 day (p =
0.058) and the 60 day (p = 0.062) values are as meaningful
and indicative of efficacy as the 90 day value (p = 0.045).
For the UP446 500 mgs/day group statistical significance
at p < 0.05 is achieved at 30 days (p = 0.001) and at 90
days (p = 0.001) but not a 60 days (p = 0.102), and for the
Celecoxib group significance at p < 0.05 was observed at
60 days (p = 0.004) and at 90 days (p = 0.021) but not a 30
days (p = 0.375).
We also found lack of agreement between the
WOMAC and the SF-36 assessments, these are not
uncommon and have been previously reported [19], still
the WOMAC is the most common and appropriate tool
for evaluation of hip and knee osteoarthritis [20].
The fact that there were positive fecal occult blood
tests (FOBT) in all the groups to include placebo makes
it difficult to use this as a safety marker. Since the total
number of positive test results in the placebo group, was
equal to or greater than the two UP446 treatment groups
(Table 10), the occurrence of positive FOBT test results
is not UP446 treatment related. The guaiac test utilizes a
colorimetric indicator that produces a detectable color
change upon oxidation [21]. The presence of occult
blood is based on oxidation of the indicator by the heme
moiety of hemoglobin, which possesses peroxidase activ-
ity. There are however, a large number of other redox
substances and peroxidases or peroxidase-like enzymes
that will test positive or otherwise interfere with this
assay [22]. Many of these interferants are present in nor-
mal dietary foods. While patients may be warned not to
eat red meat or certain fruits and vegetables, to avoid use
of aspirin or other nonsteroidal anti-inflammatory drugs
(NSAIDs), and to avoid ingesting vitamin C, e.g., orange
juice, all for the 72 hour period before testing, strict com-
pliance with these instructions is likely poor.
The baseline average systolic blood pressures for the
study groups range from a mean of 134 to 159; thus all
groups are pre-hypertensive or overtly hypertensive as
defined by the American Heart Association. The high
baseline systolic blood pressures combined with the
reported increased physical activity and the observed
weight loss for all three of the treatment groups is likely to
account for the beneficial reduction in systolic blood pres-
sure with the result that participants in the treatment
groups are closer to desirable blood pressure values as per
the American Heart Association Guidelines, less 120 mm
Hg Systolic and less than 80 mm Hg Diastolic. Notably
maximal reduction in systolic blood pressure was achieved
after 30 days dosing with no further reduction observed
after dosing for 90 days. Diastolic blood pressure and rest-
ing pulse did not change during the course of the study.
All active treatment groups experienced weight loss,
with BMI changes of between 1.6-2.4 kg/m
2.T h es t u d y
participants reported no other adverse events and the clin-
ical laboratory evaluations showed no abnormal results
that would be indicative of abnormal nutritional status or
metabolism. Per protocol the study participants had no
dietary or exercise restrictions. These changes can be
attributed to increased physical activity reported by study
participants as a result of improved mobility and reduced
discomfort associated with treatment regimens.
Conclusion
In summary the results of the present study provide
data that supports the use of UP446 at 250 mg/day and
at 500 mg/day for the effective management of the clini-
cal course of osteoarthritis. Significant improvement of
osteoarthritis symptoms was noticed after 30, 60 and 90
Table 10 Fecal Occult Blood (FOB)







Visit Baseline Positive 0 0 0 0
30 Days Positive 0 0 2 1
90 Days Positive 3 5 5 4
Total per study period 3 5 7 5
Table 11 Other reported adverse events
Condition Observations Treatment
Hypertension 1 UP446 250 mg
Varicose veins 1 UP446 250 mg
Fluid in knee 1 UP446 250 mg
Reduced flexibility 1 Placebo
Psoriasis 2 UP446 250 and 500 mg
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day. UP446 at 250 mg/day and 500 mg/day is signifi-
cantly more effective than Celecoxib 200 mg/day for the
reduction of function incapacity caused by osteoarthritis,
within 30 days (p = 0.010) of treatment and UP446 500
mgs is more effective than celecoxib for reduction of
pain at 30 days (p = 0.020)The proprietary plant extract
was well tolerated. Symptomatic adverse events and
incident of positive fecal occult blood were comparable
to the placebo group. No other serious adverse events
were observed.
On the basis of the positive findings in this pilot trial
of UP446 we concluded that the mechanism of dual
COX/LOX inhibition may confer clinical safety and effi-
cacy benefits comparable to or, in some cases superior
to traditional NSAID treatment, offering an effective
alternative option in a dietary supplement for managing
discomfort associated with OA. Based on the prelimin-
ary evidence of this pilot study an additional study in
larger patient population is currently underway to
further assess the safety and efficacy of UP446.
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